William Blair analyst Lachlan Hanbury-Brown initiated coverage of Harrow (HROW) with an Outperform rating and $63 fair value estimate. Harrow is a commercial-stage pharmaceutical company focused exclusively on ophthalmology, the analyst tells investors in a research note. The firm says the company started out as a compounding pharmacy business but has expanded into branded pharmaceuticals by acquiring a large portfolio of branded therapies that offer an attractive growth and margin profile. The recent launch of Harrow’s access and affordability program, Vevye Access for All, “is rapidly accelerating growth,” contends Blair. The firm believes the company is still early in the adoption for the product and sees the recent reintroduction of Triesence as a complementary growth driver in this segment.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Harrow acquires U.S. commercial rights to BYQLOVI 0.05% from Formosa
- Harrow acquires commercial rights for Byqlovi 0.05%
- Harrow Health’s Earnings Call: Strong Growth Amid Challenges
- Harrow price target lowered to $54 from $58 at Craig-Hallum
- Harrow price target raised to $60 from $57 at H.C. Wainwright